Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence.
about
Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposurePharmacokinetics of morphine infusion in premature neonates.Detection of morphine-3-sulfate and morphine-6-sulfate in human urine and plasma, and formation in liver cytosol.Morphine sulphation in childrenLong term high dose morphine, ketamine and midazolam infusion in a child with burns.The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteersMorphine glucuronidation in premature neonatesEffects of morphine metabolites on micturition in normal, unanaesthetized rats.Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children.Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.Controversies in cancer pain. Medical perspectives.Evaluation of the accuracy of a pharmacokinetically-based patient-controlled analgesia system.Patient-controlled analgesic administration. A comparison of steady-state morphine infusions with bolus doses.The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.Morphine metabolism in children.Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.Morphine metabolism in neonates and infants.Morphine-6-glucuronide has high affinity for the opioid receptor.Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.Evidence for analgesia mediated by peripheral opioid receptors in inflamed synovial tissue.Selective upregulation of functional mu-opioid receptor splice variants by chronic opioids.Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays.Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors.[Drug therapy for tumor pain I. Properties of non-opioids and opioids.].Lower urinary recovery of oral morphine in Saudi Arabian cancer patients compared to Swedish cancer patients.Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium.PHARMACOKINETICS OF DEXTROMORAMIDE IN SURGICAL PATIENTS
P2860
Q24652234-2BC23E8A-792F-4CBF-912D-B1B2605E6201Q33623615-AFE3B90E-0A8B-4B1C-A1F0-19A31D3503E9Q34292621-CC183F8D-0D07-4226-AE63-14DAB8D9ED7EQ34357862-418F5C6B-1652-41CF-8C71-0DCCA018386BQ34357872-18215284-6243-477B-AE72-2060E7A2CBF9Q34397089-B591E9C9-73B0-4DD4-A963-E8AB2688770CQ34403737-D3EC4D32-4A17-4752-9565-62448481502FQ36330261-45C5871F-2FFC-4400-80D7-4C14BC054824Q37065797-E004E57D-EF11-4B79-8589-7AA835EA39F7Q37124058-539E2D31-5E02-4176-BFDA-872C88642D17Q37142434-B4D8A47D-F62E-4491-B24F-354044300926Q38348701-D574CD11-06F5-4F02-A6F7-42A84D8A571DQ39504927-33DACC49-64E3-4E86-9759-CE54E7E4271FQ39511015-339D5207-2CA5-401C-9C6F-CA1A6402EAC7Q41170052-25A85593-3322-452D-BE19-386DB1F7E865Q41859602-D4DE7E2D-9F61-4CF0-980E-64833A2735B9Q41980769-1BC2B057-32F9-461E-B555-17EF5629FADDQ43224470-D0B8D4FE-463D-48C8-A181-D70FAA56EA06Q43605189-84BA938E-4EA6-46F9-A680-5412D2F84865Q43968416-7159200B-F882-4B52-8967-B09489D82FFEQ44332013-F82157D8-445C-45B0-8F2C-B2159A965C48Q44334406-12A9206B-A94E-43B9-B142-F6E0C536DF44Q44862502-FA706049-7687-4FDB-9143-6379090149A1Q51726844-AB58533D-206D-4CDC-806A-5ADA12C23D27Q51739314-D115AE54-80AE-44AC-A36A-558194E591CBQ52292836-5567BCB5-AD39-47C5-BDB5-CF3C91615F9FQ54672775-054436C6-83D7-4D2D-A23C-9DE640D2F800Q55114510-BDC5F291-B1E4-46E6-A938-81B02FDC7440Q57479949-2D444A1C-9FE4-4870-A43E-52EA28294811
P2860
Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence.
description
1983 nî lūn-bûn
@nan
1983 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1983 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
name
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@ast
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@en
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@nl
type
label
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@ast
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@en
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@nl
prefLabel
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@ast
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@en
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@nl
P2093
P2860
P1476
Morphine metabolism in cancer ...... oinduction or dose-dependence.
@en
P2093
P2860
P356
10.1111/J.1365-2125.1983.TB02148.X
P407
P577
1983-07-01T00:00:00Z